Stock Scorecard



Stock Summary for Fulgent Genetics Inc (FLGT) - $19.68 as of 6/30/2025 5:52:32 PM EST

Total Score

13 out of 30

Safety Score

41 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for FLGT

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for FLGT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for FLGT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for FLGT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for FLGT (41 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 8
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 5
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for FLGT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT - Fulgent Genetics ( NASDAQ:FLGT ) 6/23/2025 4:53:00 PM
Bragar Eagel & Squire, P.C. Is Investigating Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm - Adtran Holdings ( NASDAQ:ADTN ) , Fulgent Genetics ( NASDAQ:FLGT ) 6/10/2025 1:00:00 AM
Bragar Eagel & Squire, P.C. Is Investigating EchoStar, Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm - Adtran Holdings ( NASDAQ:ADTN ) , Fulgent Genetics ( NASDAQ:FLGT ) 6/3/2025 1:00:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT - Fulgent Genetics ( NASDAQ:FLGT ) 6/2/2025 5:27:00 PM
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Fulgent Genetics, Inc. ( NASDAQ: FLGT ) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm - Fulgent Genetics ( NASDAQ:FLGT ) 5/28/2025 10:10:00 PM
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm - Fulgent Genetics ( NASDAQ:FLGT ) 5/23/2025 1:00:00 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT - Fulgent Genetics ( NASDAQ:FLGT ) 5/22/2025 1:46:00 PM
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc - Fulgent Genetics ( NASDAQ:FLGT ) 5/16/2025 12:48:00 PM
Fulgent Genetics, Inc. ( FLGT ) Q1 Earnings and Revenues Beat Estimates 5/2/2025 12:10:00 PM
Hims & Hers Health ( HIMS ) Moves 5.7% Higher: Will This Strength Last? 3/24/2025 12:01:00 PM

Financial Details for FLGT

Company Overview

Ticker FLGT
Company Name Fulgent Genetics Inc
Country USA
Description Fulgent Genetics, Inc., provides COVID-19 testing and genetic testing services to physicians with clinically actionable diagnostic information. The company is headquartered in Temple City, California.
Sector Name LIFE SCIENCES
Industry Name SERVICES-MEDICAL LABORATORIES
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History

Last Day Price 19.68
Price 4 Years Ago 100.59
Last Day Price Updated 6/30/2025 5:52:32 PM EST
Last Day Volume 362,419
Average Daily Volume 255,633
52-Week High 25.11
52-Week Low 14.57
Last Price to 52 Week Low 35.07%

Valuation Measures

Trailing PE N/A
Industry PE 29.18
Sector PE 40.73
5-Year Average PE 25.71
Free Cash Flow Ratio 8.90
Industry Free Cash Flow Ratio 37.68
Sector Free Cash Flow Ratio 32.54
Current Ratio Most Recent Quarter 6.32
Total Cash Per Share 2.21
Book Value Per Share Most Recent Quarter 36.81
Price to Book Ratio 0.53
Industry Price to Book Ratio 2.14
Sector Price to Book Ratio 30.79
Price to Sales Ratio Twelve Trailing Months 2.04
Industry Price to Sales Ratio Twelve Trailing Months 2.37
Sector Price to Sales Ratio Twelve Trailing Months 35.57
Analyst Buy Ratings 0
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 30,443,600
Market Capitalization 599,130,048
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY -98.60%
Annual Earnings Growth 74.55%
Reported EPS 12 Trailing Months -1.33
Reported EPS Past Year 0.04
Reported EPS Prior Year 0.49
Net Income Twelve Trailing Months -40,776,000
Net Income Past Year -42,708,000
Net Income Prior Year -167,825,000
Quarterly Revenue Growth YOY 13.90%
5-Year Revenue Growth 54.19%
Operating Margin Twelve Trailing Months -27.00%

Balance Sheet

Total Cash Most Recent Quarter 67,281,000
Total Cash Past Year 55,144,000
Total Cash Prior Year 97,473,000
Net Cash Position Most Recent Quarter 65,323,000
Net Cash Position Past Year 52,651,000
Long Term Debt Past Year 2,493,000
Long Term Debt Prior Year 2,964,000
Total Debt Most Recent Quarter 1,958,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 1,133,228,000
Total Stockholder Equity Prior Year 1,136,101,000
Total Stockholder Equity Most Recent Quarter 1,127,178,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -31,614,000
Free Cash Flow Per Share Twelve Trailing Months -1.04
Free Cash Flow Past Year -19,255,000
Free Cash Flow Prior Year 4,796,000

Options

Put/Call Ratio 0.09
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.09
MACD Signal 0.19
20-Day Bollinger Lower Band 15.33
20-Day Bollinger Middle Band 18.71
20-Day Bollinger Upper Band 22.09
Beta 1.07
RSI 43.17
50-Day SMA 19.59
150-Day SMA 27.10
200-Day SMA 37.98

System

Modified 6/28/2025 12:06:37 AM EST